Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports

S W Lim; D Gillis; W Smith; P Hissaria; H Greville; C A Peh

doi:10.1111/j.1445-5994.2006.01055.x

Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports

Intern Med J. 2006 Apr;36(4):260-2. doi: 10.1111/j.1445-5994.2006.01055.x.

Authors

S W Lim¹, D Gillis, W Smith, P Hissaria, H Greville, C A Peh

Affiliation

¹ Immunology Department, Royal Adelaide Hospital, Adelaide, South Australia, Australia. slim1@mail.rah.sa.gov.au

PMID: 16640745
DOI: 10.1111/j.1445-5994.2006.01055.x

Abstract

Rituximab is a chimeric monoclonal antibody specific for human CD20 that causes selective transient depletion of the CD20+ B-cell subpopulation. We report the first case of systemic lupus erythematosus (SLE) pneumonitis resistant to conventional treatments that responded well to rituximab and review current reports on the use of rituximab in SLE.

Publication types

Case Reports
Review

MeSH terms

Adult
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived
Exercise Tolerance / drug effects
Female
Humans
Immunologic Factors / therapeutic use*
Lupus Erythematosus, Systemic / complications
Lupus Erythematosus, Systemic / drug therapy*
Pneumonia / drug therapy*
Pneumonia / etiology
Rituximab

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Immunologic Factors
Rituximab